Seagen's ADCETRIS Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival At 12 Months In Phase 2 Trial Of Patients With Early Stage Classical Hodgkin Lymphoma
Seagen's ADCETRIS Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival At 12 Months In Phase 2 Trial Of Patients With Early Stage Classical Hodgkin Lymphoma
在针对早期经典霍奇金淋巴瘤患者的2期试验中，Seagen的ADCETRIS Plus新型免疫疗法组合可在12个月内实现100％的无进展存活率
– 88% of patients with advanced stage classical Hodgkin Lymphoma in trial remained progression free at 24 months –
— 在试验的晚期经典霍奇金淋巴瘤患者中，有 88% 在24个月时仍无进展 —
– Investigational regimen that eliminates two commonly used chemotherapy agents, vinblastine and bleomycin, continues to show consistent safety and tolerability profile, with no cases of febrile neutropenia and no new safety signals observed –
— 消除两种常用化疗药物（长春碱和博来霉素）的研究方案继续显示出一致的安全性和耐受性，没有出现发热性中性粒细胞减少症病例，也没有观察到新的安全信号 —